ProCE Banner Series

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

Join us to learn more about how to optimally integrate HER2-targeted antibody‒drug conjugate therapy for your patients with NSCLC. During this live meeting, you will have the opportunity to interact with an expert and ask questions at the end of the session. Register today!

To Register: Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE
  | AMA
  | ANCC
  | ANCC
Who Should Attend

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC.

All Events

Upcoming Events

January

23

2024

Copy_785_Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Decatur, Texas

Past Events

October

31

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event | Host Group NY, Queens, New York

November

01

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Private Event | Host Group ID, Post Falls, Idaho

November

08

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

7:15 AM - 8:15 AM Pacific Time (PT)

Virtual

Private Event | Host Group WA, Spokane, Washington

November

09

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

Private Event, Gainesville, Florida

November

13

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group MD, Baltimore, Maryland

November

16

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group DC, Washington, District of Columbia

December

13

2023

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy [Open Registration]

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

Private Event, Lexington, Kentucky

January

17

2024

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Virtual Event | Host Group in NY, Plattsburgh, New York

January

23

2024

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Decatur, Texas

January

30

2024

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

8:30 AM - 9:30 AM Eastern Time (ET)

Virtual

Private Event | Host Group VT, Bennington, Vermont

Faculty

ProCE Banner Faculty
Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

ProCE Banner Faculty
Lyudmila Bazhenova, MD

Lung Cancer Unit Leader
Director 
Hematology and Oncology Training Program
University of California 
San Diego, California

ProCE Banner Faculty
Ticiana Leal, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Director, Thoracic Medical Oncology Program
Winship Cancer Institute
Emory University
Atlanta, Georgia

ProCE Banner Faculty
Nisha Mohindra, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine of Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

ProCE Banner Faculty
Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

ProCE Banner Faculty
Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Topics

  • Welcome and introduction
  • Case-guided discussions
    • HER2 biology, expression, and background in NSCLC and expert-recommended genomic testing strategies
    • Integration of HER2-targeted ADCs into the NSCLC treatment landscape through expert-guided review of current and emerging clinical data
    • Individualized adverse event identification and management strategies with HER2-targeted ADC therapy
  • Question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC). 

Target Audience
This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate optimal testing and assessment strategies to identify patients most likely to benefit from HER2-targeted antibody-drug conjugate therapy
  • Develop treatment plans using HER2-directed antibody-drug conjugates considering recent FDA approvals, emerging data and individualized patient characteristics
  • Prepare strategies for effective identification and management of AEs associated with HER2-targeted therapies considering pharmacologic activity, patient history, and disease- versus drug-related symptoms

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-219-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.